A retrospective study analysing risk of bleeding and significant thrombocytopenia in cancer patients treated with immune checkpoint inhibitors
Latest Information Update: 15 Jun 2020
At a glance
- Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Breast cancer; Gastrointestinal cancer; Lung cancer; Malignant melanoma; Urogenital cancer
- Focus Adverse reactions
Most Recent Events
- 15 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology